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SUMMARY 47 
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-48 
positive locally advanced or metastatic breast cancer (LA/MBC). We investigated 49 
whether the selective estrogen receptor degrader fulvestrant could improve 50 
progression-free survival versus anastrozole in postmenopausal patients who had not 51 
received prior endocrine therapy. 52 
METHODS: In this Phase 3, randomised, double-blind trial (FALCON), eligible 53 
patients, from 113 centres in 20 countries, were endocrine therapy-naïve, had estrogen 54 
receptor and/or progesterone receptor-positive LA/MBC, WHO performance status 0–55 
2, and ≥1 measurable/non-measurable lesion(s). Patients were randomised (1:1) to 56 
fulvestrant (500 mg IM; Days 0, 14, 28, then each 28 days) or anastrozole (1 mg orally 57 
daily) using a computer-generated randomisation scheme. The primary endpoint was 58 
progression-free survival (PFS), determined by RECIST 1·1, intervention by surgery 59 
or radiotherapy due to disease deterioration, or death (any cause). This trial is 60 
registered at ClinicalTrials.gov (NCT01602380). 61 
FINDINGS: Between 17 October 2012 and 11 July 2014, 524 patients were enrolled 62 
and 462 patients were randomised (fulvestrant, n=230; anastrozole, n=232). Primary 63 
endpoint was met, as shown by a statistically significant improvement in PFS for 64 
fulvestrant vs anastrozole (hazard ratio [HR] 0·797; 95% confidence interval [CI] 65 
0·637–0·999; p=0·0486). Median PFS was 16·6 (95% CI 13·83–20·99) vs 13·8 (95% 66 
CI 11·99–16·59) months for fulvestrant and anastrozole, respectively. Most common 67 
adverse events (AEs) were arthralgia (16·7% vs 10·3%) and hot flushes (11·4% vs 68 
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10·3%); 7·0% vs 4·7% discontinued due to AEs with fulvestrant and anastrozole, 69 
respectively. 70 
INTERPRETATION: Results confirm the superior efficacy of fulvestrant over 71 
anastrozole in postmenopausal women with hormone receptor-positive LA/MBC who 72 
have not received prior endocrine therapy. 73 
FUNDING: AstraZeneca 74 
75 
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INTRODUCTION 76 
First-line treatment recommendations for postmenopausal women with hormone 77 
receptor-positive (estrogen receptor [ER], and/or progesterone receptor [PgR]) locally 78 
advanced or metastatic breast cancer includes endocrine therapy with a 79 
third-generation aromatase inhibitor (AI; anastrozole, letrozole, exemestane) or 80 
tamoxifen.1–3 In hormone receptor-positive disease, third-generation AIs have 81 
increased efficacy compared with tamoxifen in terms of time to progression.4–8 82 
Fulvestrant, a selective ER degrader (SERD) that blocks ER function by inducing ER 83 
degradation,9 is approved for postmenopausal women with hormone receptor-positive 84 
advanced breast cancer and disease progression following antiestrogen therapy.10,11 85 
The 500 mg dose of fulvestrant was approved based on data from the Phase 3, 86 
double-blind Comparison of Faslodex in Recurrent or Metastatic Breast Cancer 87 
(CONFIRM) study that compared fulvestrant 500 mg with fulvestrant 250 mg in 88 
patients with hormone receptor-positive advanced breast cancer who experienced 89 
progression after prior endocrine therapy.12 In CONFIRM, progression-free survival 90 
(PFS; hazard ratio [HR] 0·80; 95% confidence interval [CI] 0·68–0·94; p=0·006)12 91 
and overall survival (OS; HR 0·81; 95% CI 0·69–0·96; p=0·02)13 were increased with 92 
fulvestrant 500 mg vs fulvestrant 250 mg. 93 
Improved efficacy of first-line treatment with fulvestrant vs anastrozole was 94 
demonstrated in a Phase 2, open-label Fulvestrant First-Line Study Comparing 95 
Endocrine Treatments (FIRST) study in postmenopausal women with hormone 96 
receptor-positive locally advanced or metastatic breast cancer.14 Fulvestrant was 97 
shown to be at least as effective as anastrozole in terms of clinical benefit rate (CBR; 98 
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72·5% [74/102] vs 67·0% [69/103], respectively; odds ratio, 1·30; 95% CI, 0·72–99 
2·38; p=0·386).14 In subsequent follow-up analyses, fulvestrant was associated with a 100 
longer PFS/time to progression (HR 0·66; 95% CI 0·47–0·92; p=0·01)15 and 101 
improved OS (HR 0·70; 95% CI 0·50–0·98; p=0·04)16 vs anastrozole. 102 
The objective of the current study was to confirm the superior PFS advantage for 103 
fulvestrant versus anastrozole observed in the FIRST study, in a double-blind Phase 3 104 
design. The population for FALCON were postmenopausal women with hormone 105 
receptor-positive locally advanced or metastatic breast cancer who had not received 106 
prior endocrine therapy, in order to avoid reducing efficacy of the control arm through 107 
exposure to adjuvant endocrine therapy. 108 
METHODS 109 
Study design 110 
The Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced 111 
breast cancer (FALCON) trial (Clinicaltrials.gov: NCT01602380) is a Phase 3 112 
randomised, double-blind, double-dummy, international, multicentre study that 113 
compared the efficacy and tolerability of fulvestrant with anastrozole in 114 
postmenopausal women with histologically confirmed ER+ and/or PgR+ locally 115 
advanced or metastatic breast cancer. 116 
Ethical approval 117 
The study was conducted in accordance with the Declaration of Helsinki and 118 
International Conference on Harmonisation/Good Clinical Practice guidelines. An 119 
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Ethics Committee or Institutional Review Board approved the final protocol at each 120 
study site. All patients provided written, informed consent. 121 
Participants 122 
Eligible patients were postmenopausal women who had a World Health Organization 123 
(WHO) performance status of 0–2, and ≥1 measurable and/or non-measurable 124 
lesion(s). Key exclusion criteria included prior hormonal treatment for breast cancer; 125 
presence of life-threatening, metastatic, visceral disease; prior systemic therapy for 126 
breast cancer, except one line of cytotoxic chemotherapy; radiation therapy if 127 
completed ≤28 days prior to randomisation (unless for bone pain control); human 128 
epidermal growth factor receptor (HER2) over-expression/gene amplification; 129 
concomitant anticancer treatment (except bisphosphonates/denosumab); systemic 130 
estrogen-containing hormone-replacement therapy (HRT) use ≤6 months prior to 131 
randomisation (see Supplementary Appendix for full inclusion and exclusion criteria).  132 
Randomisation and masking 133 
Patients were randomised sequentially (1:1) to fulvestrant 500 mg or anastrozole 1 mg 134 
using a computer-generated randomisation scheme and an integrated voice/web 135 
response system. Patients were stratified at randomisation according to locally 136 
advanced or metastatic breast cancer; prior or no prior treatment with chemotherapy 137 
for locally advanced or metastatic breast cancer; and measurable or non-measurable 138 
disease. 139 
Study drugs were labelled using a unique identifier linked to the randomisation 140 
scheme. The active study drug and placebo for fulvestrant (pre-filled syringes) and 141 
anastrozole (tablets) were identically packaged to maintain blinding. 142 
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Procedures 143 
Study treatment was initiated at randomisation (Day 0). Fulvestrant (plus daily 144 
anastrozole placebo) was administered on Days 0, 14 (±3), 28 (±3), and every 28 (±3) 145 
days thereafter as two 5 mL intramuscular injections at each visit. No fulvestrant dose 146 
reductions were permitted. Anastrozole (plus fulvestrant placebo on Days 0, 14, 28, 147 
and every 28 days thereafter) was administered once daily as a single tablet. Treatment 148 
continued until objective disease progression or other criteria for discontinuation were 149 
met in terms of adverse events (AEs), protocol non-adherence, or patient’s decision to 150 
withdraw. 151 
Study visits occurred at screening (Day -28 to -1), randomisation (Day 0), Day 14, 152 
every 4 weeks from Week 4 to 24 and every 12 weeks thereafter until disease 153 
progression. Safety and tolerability were assessed at each study visit, and for up to 8 154 
weeks after the last fulvestrant/placebo injection. HRQoL questionnaires were 155 
administered at baseline and at 3-monthly intervals. Following disease progression or 156 
treatment discontinuation, HRQoL questionnaires will be administered at 6-monthly 157 
until a final OS analysis. 158 
Outcomes 159 
The primary endpoint of the study was to demonstrate the superior PFS of patients 160 
treated with fulvestrant vs anastrozole. A progression event was determined based on 161 
tumour assessments performed locally by each investigator, and was defined by 162 
Response Evaluation Criteria in Solid Tumours (RECIST) 1·1, or 163 
surgery/radiotherapy for worsening of disease, or death from any cause.  164 
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Secondary endpoints included objective response rate (ORR; best overall response of 165 
either complete response [CR] or partial response [PR] in patients with measurable 166 
disease at baseline), duration of response (DoR), and expected duration of response 167 
(EDoR), CBR (best overall response of CR, PR, or stable disease [SD] ≥24 weeks), 168 
duration of clinical benefit (DoCB), expected duration of clinical benefit (EDoCB), 169 
and OS (time from randomisation until death by any cause). 170 
Health-related quality of life (HRQoL) was assessed using the Trial Outcome Index 171 
(TOI)17 derived from the Functional Assessment of Cancer Therapy for Breast Cancer 172 
(FACT-B) questionnaire, and FACT-B total score. 173 
Safety and tolerability assessments included AEs (graded according to Common 174 
Terminology Criteria for Adverse Event [CTCAE], version 4·0), serious AEs (SAEs), 175 
discontinuations due to AEs, deaths due to AEs, and pre-defined AEs of special 176 
interest (joint disorders and back pain) were reported throughout the study. Laboratory 177 
parameters, electrocardiogram (ECG) recordings, physical examination, and vital 178 
signs were monitored at pre-specified time points throughout the study. The safety 179 
analysis population was used for all safety outcome variables and included all patients 180 
who received at least one dose of randomised treatment (including placebo) according 181 
to the actual treatment initially received. 182 
Statistical analysis 183 
For the primary outcome, PFS was evaluated at a single time point when 184 
approximately 306 progression events had occurred. Randomisation of approximately 185 
450 patients was planned to achieve 306 progression events. It was calculated that if 186 
0·69 is the true PFS HR for the comparison of fulvestrant vs anastrozole, this number 187 
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of events would provide 90% power for statistical significance at the 5% two-sided 188 
level. A PFS HR of 0·80 would deliver a statistically significant difference for the 189 
primary outcome. The primary analysis for this study was conducted in the intent-to-190 
treat (ITT) population comprising all randomised patients. 191 
Comparison of PFS for fulvestrant vs anastrozole was performed using a stratified 192 
log-rank test at the two-sided 5% significance level in the ITT population. Strata 193 
included were prior chemotherapy for locally advanced or metastatic disease and 194 
measurable disease; locally advanced vs metastatic disease was not included because 195 
only a small number of patients had locally advanced disease. Results are presented as 196 
an estimate of the HR, associated 95% CI, and p value. An interim analysis of OS was 197 
performed at the time of PFS analysis, and OS was analysed in the same way as PFS. 198 
OS and ORR were tested using a multiple testing procedure with an alpha-exhaustive 199 
recycling strategy to control type-I error at the overall alpha level.18 CBR was 200 
analysed using a logistic regression model including the same stratification factors as 201 
for PFS and examination of odds ratio of the two treatment groups. ORR was analysed 202 
in the same way as CBR; however, measurable disease was not included in the model. 203 
Kaplan-Meier plots were produced for DoCB and DoR. EDoCB and EDoR are 204 
methodologies designed to provide an unbiased treatment comparison of DoCB and 205 
DoR by including all randomised patients (rather than just responding patients), and 206 
were calculated using the method of Ellis et al.19 EDoR and EDoCB allow a statistical 207 
comparison to be made on the duration of response and clinical benefit between the 208 
two treatment arms. An analysis of time to deterioration of TOI and FACT-B total 209 
score was performed as described for PFS. 210 
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A subgroup analysis was performed on PFS data (ITT) for the following baseline 211 
covariates: ER+ and PgR+ (yes/no); metastatic disease (yes/no); concomitant use of 212 
bisphosphonates (yes/no); measurable disease (yes/no); prior chemotherapy for locally 213 
advanced or metastatic breast cancer (yes/no); geographic region; prior systemic 214 
estrogen containing HRT (yes/no); and visceral disease (yes/no). HRs and 95% CI 215 
were calculated, and a Kaplan-Meier was generated for each subgroup. A global 216 
interaction test was performed using a Cox-proportional hazard model to evaluate if 217 
the treatment effect was consistent across the covariates. A post hoc interaction test to 218 
assess for consistency of the treatment effects across the visceral and non-visceral 219 
subgroups was also performed. 220 
All patients who received at least one dose of randomised treatment were included in 221 
the safety population. AEs were summarised descriptively using Medical Dictionary 222 
for Regulatory Activities (MedDRA) preferred terms. 223 
This trial is registered at ClinicalTrials.gov, number NCT01602380. 224 
Role of the funding source 225 
This study was designed and funded by AstraZeneca, who was involved in the 226 
reviewing and interpretation of data, the writing of the manuscript, and in the decision 227 
to submit for publication. 228 
All authors had access to all the data and were responsible for the decision to submit 229 
the manuscript.  230 
RESULTS 231 
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Between 17 October 2012 and 11 July 2014, a total of 524 patients were enrolled. Of 232 
these, 462 patients were randomised (ITT; Figure 1): 230 received fulvestrant and 232 233 
received anastrozole at 113 centres in 20 countries in Asia, Europe, North America, 234 
South America, and South Africa. Data cut-off was 11 April 2016. 235 
Two patients in the fulvestrant group did not receive study treatment following 236 
randomisation (patient decision); therefore, the safety population comprised 228 and 237 
232 patients in the fulvestrant and anastrozole groups, respectively. 238 
In total, 14 and 13 protocol deviations related to eligibility criteria were observed in 239 
the fulvestrant and anastrozole arms, respectively. Three patients were reported to 240 
have received prior endocrine therapy. These protocol deviations were considered 241 
unlikely to affect the interpretation of study data. 242 
Baseline demographic and disease characteristics were generally well balanced 243 
between groups (Table 1).  244 
There were 309 progression events at data cut-off; of these, 143/230 (62·2%) and 245 
166/232 (71·6%) occurred in the fulvestrant and anastrozole groups, respectively. 246 
Fulvestrant was associated with a statistically significant improvement in PFS 247 
compared with anastrozole (HR 0·797; 95% CI 0·637–0·999; p=0·0486; Figure 2). 248 
Median PFS was 16·6 months (95% CI 13·83–20·99) with fulvestrant and 13·8 249 
months (95% CI 11·99–16·59) with anastrozole (difference in medians, 2·8 months). 250 
Table 2 shows the proportions of patients with CR, PR, and SD. In patients with 251 
measurable disease, ORR was 46·1% (89/193) with fulvestrant and 44·9% (88/196) 252 
with anastrozole (odds ratio 1·07; 95% CI 0·72–1·61; p=0·7290). DoR in patients 253 
with measurable disease at baseline is shown in Supplementary Figure 1a. Median 254 
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DoR was longer in the fulvestrant arm than the anastrozole arm (20·0 [95% CI 15·90–255 
27·63] and 13·2 [95% CI 10·64–16·72] months, respectively). EDoR was 11·4 and 256 
7·5 months, respectively (EDoR ratio 1·52; 95% CI  1·03–2·26; p=0·0367). 257 
CBR was 78·3% (180/230) and 74·1% (172/232) with fulvestrant and anastrozole, 258 
respectively (odds ratio 1·25; 95% CI 0·82–1·93; p=0·3045). DoCB in patients with 259 
clinical benefit is shown in Supplementary Figure 1b. Median DoCB was 22·1 (95% 260 
CI 18·46–24·87) and 19·1 (95% CI 16·53–20·47) months for fulvestrant and 261 
anastrozole, respectively. The EDoCB was 21·9 months in the fulvestrant arm and 262 
17·5 months in the anastrozole arm (EDoCB ratio 1·26; 95% CI 0·99–1·59; 263 
p=0·0561). 264 
Median OS could not be calculated as currently there is insufficient follow-up (31% 265 
maturity). At data cut-off, 67/230 (29·1%) and 75/232 (32·3%) patients in the 266 
fulvestrant and anastrozole groups, respectively, had died (HR 0·88; 95% CI 0·63–267 
1·22; p=0·4277). 268 
Treatment effects on PFS were largely consistent across the pre-specified patient 269 
subgroups (global interaction test, p=0·1061), with some exceptions noted: patients 270 
with prior chemotherapy for locally advanced or metastatic disease; patients with 271 
non-measurable disease; patients who were not ER+ and PgR+ at baseline; and 272 
patients with visceral disease (Figure 3a). For patients with non-visceral disease, the 273 
HR was 0·59 (95% CI 0·42–0·84), with median PFS of 22·3 (95% CI 16·62–32·79) 274 
vs 13·8 (95% CI 11·04–16·59) months for fulvestrant and anastrozole, respectively 275 
(Figure 3b). In the visceral disease subgroup, the HR was 0·99 (95% CI 0·74–1·33), 276 
with median PFS of 13·8 (95% CI 11·04–16·53) months for fulvestrant and 15·9 277 
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(95% CI 11·27–16·89) months for anastrozole. A post hoc interaction test to assess for 278 
consistency of the treatment effects across the visceral and non-visceral subgroups 279 
gave p=0·0092.  280 
At data cut-off, median duration of actual exposure to fulvestrant was 14·7 months 281 
(range 0·9–37·7) and to anastrozole was 13·9 months (range 0·2–36·0). In total, 282 
166/228 (72·8%) and 173/232 (74·6%) patients reported an AE in the fulvestrant and 283 
anastrozole groups, respectively. Table 3 presents AEs with an incidence >5% in 284 
either group. SAEs were reported by 30/228 (13·2%) vs 31/232 (13·4%) patients 285 
receiving fulvestrant or anastrozole, respectively (Supplementary Table 1 presents 286 
SAEs considered causally related to treatment). Overall, 16/228 (7·0%) and 11/232 287 
(4·7%) patients in the fulvestrant and anastrozole groups, respectively, discontinued 288 
due to AEs (Supplementary Table 2). Grade 3 or worse AEs were reported by 51/228 289 
(22·4%) and 41/232 (17·7%) patients receiving fulvestrant and anastrozole, 290 
respectively; none occurred in >5% of patients in either group. There were 6/228 291 
(2·6%) and 7/232 (3·0%) deaths due to AEs in the fulvestrant and anastrozole groups, 292 
respectively. No deaths due to AEs were considered causally related to treatment. 293 
AEs of special interest (joint disorders and back pain) were reported by 59/228 294 
(25·9%) and 42/232 (18·1%) patients in the fulvestrant and anastrozole groups, 295 
respectively. All AEs of special interest were mild or moderate in severity (Grade 1 or 296 
2), with the exception of one patient (1/228 [0·4%]) in the fulvestrant group who had 297 
Grade 3 back pain. No AEs of special interest led to treatment interruption, or had a 298 
fatal outcome. No SAEs of special interest were reported. 299 
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Overall, no clinically significant changes in laboratory parameters, ECG recordings, 300 
physical examination, or vital signs were observed in either group. 301 
Mean FACT-B and TOI scores were maintained and similar in both treatment groups. 302 
Time to deterioration was not statistically significantly different between treatment 303 
arms for both TOI scores (HR 0·90; 95% CI 0·70–1·15; p=0·4008) and FACT-B total 304 
score (HR 0·84; 95% CI 0·66–1·07; p=0·1594). 305 
DISCUSSION 306 
The primary endpoint of this Phase 3 study was met, with patients receiving 307 
fulvestrant experiencing statistically significantly longer PFS than patients receiving 308 
anastrozole, confirming the hypothesis that fulvestrant is a more efficacious treatment 309 
than anastrozole in postmenopausal women with hormone receptor-positive locally 310 
advanced or metastatic breast cancer who have not received prior treatment with 311 
endocrine therapy. This represents a meaningful and relevant finding for which 312 
clinical data are limited.20 Strengths of this study are the inclusion of a diverse patient 313 
population, the double-dummy study design, and the use of a standard-of-care 314 
comparison arm. Unlike many other studies where patients were allowed to receive 315 
prior adjuvant endocrine therapy, patients in the FALCON study were completely 316 
endocrine therapy-naïve and were even limited in their use of HRT prior to 317 
randomisation to greater than 6 months, given the known effect of HRT withdrawal. 318 
Therefore, this study provides a direct comparison of the therapeutic efficacy between 319 
the SERD fulvestrant and a third-generation AI without the confounding effects of 320 
prior adjuvant endocrine therapy exposure of any type. The HR for PFS seen in this 321 
study (0·797) is similar to the improvement shown by third-generation AIs over 322 
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tamoxifen.4–8 In addition to the primary endpoint results, pre-defined subgroup 323 
analyses were performed. The test for heterogeneity was not statistically significant 324 
across all the subgroups although it was noted that potential enhanced treatment 325 
effects with fulvestrant vs anastrozole were seen in some subgroups, including 326 
patients with non-visceral disease compared with visceral disease. This latter 327 
observation requires further study. 328 
The FALCON data add to the extensive data on the efficacy of fulvestrant in patients 329 
with advanced breast cancer, and consolidate the evidence for superior efficacy for 330 
fulvestrant over a third-generation AI, initially raised by the results of the Phase 2 331 
FIRST study, where the majority of patients were also endocrine-naïve.14–16 332 
The superiority of fulvestrant over anastrozole in an endocrine therapy-naïve patient 333 
population warrants future clinical evaluation of fulvestrant in other endocrine 334 
therapy-naïve patient populations, such as the (neo)adjuvant setting, where a Phase 3 335 
comparison with anastrozole for 6 months before surgery is currently underway 336 
(NCT01953588). The superior efficacy of fulvestrant was not associated with an 337 
enhanced response rate. The PFS advantage appears to be driven by the more durable 338 
responses associated with fulvestrant treatment as shown by the DoR and EDoR 339 
analyses. Since aromatase inhibition is prone to resistance generated by ESR1 340 
mutation,21 one possibility for the PFS advantage is that fulvestrant is less prone to 341 
this resistance mechanism. The recent advent of circulating tumour DNA analysis 342 
should allow this hypothesis to be further evaluated. In preliminary studies it does 343 
appear that fulvestrant retains activity against tumours that harbour an ESR1 344 
mutation.22 345 
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The AE profile observed was generally consistent with the known safety profiles of 346 
fulvestrant and anastrozole. The most common AE reported with fulvestrant in the 347 
FALCON study was arthralgia, which occurred at a numerically higher frequency to 348 
that noted in the FIRST study (16·7% [38/228] and 9·9%, respectively);14 however, no 349 
patients discontinued as a result. More patients in the fulvestrant group experienced 350 
myalgia than in the anastrozole group. Less than 2% of patients in either treatment 351 
group experienced SAEs causally related to treatment or discontinued treatment due to 352 
AEs, and no treatment-related deaths occurred.  353 
An alternative to first-line fulvestrant has been established by the results of the 354 
Palbociclib Ongoing Trials in the Management of Breast Cancer (PALOMA-2) trial 355 
(NCT01740427), which excluded patients resistant to AIs, and the Mammary 356 
Oncology Assessment of LEE011’s (ribociclib) Efficacy and Safety (MONALEESA-2 357 
trial (NCT01958021). These studies  investigated the efficacy of the cyclin-dependent 358 
kinases 4 and 6 (CDK4/6) inhibitors palbociclib or ribociclib plus letrozole, 359 
respectively, vs letrozole alone in postmenopausal women who had not received prior 360 
systemic treatment for advanced breast cancer.23,24 Statistically significant 361 
improvements in PFS were shown for palbociclib plus letrozole (HR 0·58; 95% CI 362 
0·46–0·72; p<0·0001) in PALOMA-2, and ribociclib plus letrozole (HR 0·56; 95% CI 363 
0·43–0·72; p=3·29 × 10-6) in MONALEESA-2 vs letrozole alone.23 Both the 364 
PALOMA-2 and MONALEESA-2 studies demonstrate that addition of a second agent 365 
from a different class is associated with improved efficacy but additional toxicity, and 366 
the potential for an increased financial burden.25 As such, the incidence of Grade 3 367 
and 4 SAEs, and permanent treatment discontinuation due to AEs (both 368 
haematological and non-haematological AEs) was greater with palbociclib plus 369 
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letrozole and ribociclib plus letrozole than letrozole alone. Thus, when considered in 370 
the context of the results from FALCON, fulvestrant provides a lower toxicity option 371 
for first-line therapy that could be favoured for patients with low or intermediate risk 372 
disease with relatively good prognosis (e.g. non visceral disease), patients with high 373 
risk disease who have comorbidities restricting the use of combination targeted 374 
therapy, patients who cannot afford a CDK4/6 inhibitor, or in countries where 375 
CDK4/6 inhibitors are not been approved by regulatory authorities.  376 
It is clearly important to identify patients likely to gain most benefit from treatment 377 
with endocrine monotherapy. Indeed, patients who achieved clinical response to 378 
fulvestrant experienced longer duration of response vs anastrozole. Thus, patients with 379 
endocrine-sensitive disease may not always require a combination treatment that is 380 
associated with greater toxicity. FALCON and PALOMA-2/MONALEESA-2 trials 381 
are not directly comparable and are immature from an OS perspective. OS results 382 
could provide additional evidence to support decisions between the use of a first-line 383 
CDK4/6 inhibitor with an AI vs fulvestrant monotherapy, particularly given the OS 384 
advantage already observed for fulvestrant over anastrozole in the FIRST study. 385 
In conclusion, the FALCON study results support the conclusion that fulvestrant is 386 
more efficacious than anastrozole on the basis of a statistically significant 387 
improvement in PFS in postmenopausal women with hormone receptor-positive 388 
locally advanced or metastatic breast cancer who have not received prior endocrine 389 
therapy. Both treatments were associated with an acceptable tolerability profile. 390 
Collectively, the efficacy and tolerability findings support the clinical effectiveness of 391 
fulvestrant in this setting. 392 
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RESEARCH IN CONTEXT PANEL 
Evidence before this study 
We performed a general search on PubMed and ClinicalTrials.gov (search terms 
‘fulvestrant 500 mg’ and ‘clinical trial’) to identify clinical studies of fulvestrant 
500 mg, a selective estrogen receptor degrader (SERD), versus any third-generation 
aromatase inhibitor. No date or language limitations were applied. From the results 
identified, we believe that the randomised, double-blind, multicentre FALCON trial 
(NCT01602380) is the first Phase 3 trial to evaluate the efficacy and safety of 
fulvestrant compared with anastrozole in hormone receptor-positive postmenopausal 
women with advanced breast cancer who have not received prior endocrine treatment, 
a clinically meaningful patient population. 
Added value of the study 
A previous open-label, Phase 2 study (the FIRST study) in postmenopausal women 
with hormone receptor-positive locally advanced or metastatic breast cancer, the 
majority of whom were endocrine-naïve, demonstrated that first-line fulvestrant was 
at least as effective as anastrozole in terms of clinical benefit rate and was superior in 
terms of time to progression and overall survival. Results from this randomised, 
double-blind, Phase 3 FALCON study therefore add to the extensive data on the 
efficacy and safety of fulvestrant in patients with advanced breast cancer, and 
consolidates evidence for superior efficacy for fulvestrant over anastrozole 
demonstrated earlier in the FIRST study. 
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Implications of all the available evidence 
The results of the FALCON study confirm that a SERD is a more efficacious 
treatment than a third-generation AI, which is the standard-of-care in first-line 
endocrine therapy for patients with hormone receptor-positive advanced breast cancer. 
These findings consolidate the known clinical effectiveness of fulvestrant and support 
the use of fulvestrant monotherapy in endocrine-naïve patients with hormone receptor-
positive advanced breast cancer. As such, the FALCON study results have important 
implications for clinical practice. 
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FIGURE LEGENDS 
Figure 1. Patient disposition 
aTwo patients in the fulvestrant 500 mg arm did not receive treatment (patient 
decision) 
bIncludes patients with disease progression 
AE=adverse event 
 
Figure 2: Kaplan-Meier curve for PFS (ITT population) 
A circle represents a censored observation 
CI=confidence interval. HR=hazard ratio. ITT=intent-to-treat. PFS=progression-free 
survival 
 
Figure 3: a) Forest plot of PFS in patient subgroups defined by pre-specified 
baseline covariates and b) Kaplan-Meier curve for PFS in patients with and 
without visceral disease (ITT population) 
A circle represents a censored observation 
CI=confidence interval. ER=estrogen receptor. HR=hazard ratio. HRT=hormone 
replacement therapy. ITT=intent-to-treat. NC=not calculable. PFS=progression-free 
survival. PgR=progesterone receptor 
 Page 28 
Table 1: Patient baseline demographics and disease characteristics (ITT 
population) 
Characteristic Fulvestrant 500 mg 
(n=230) 
n (%) 
Anastrozole 1 mg 
(n=232) 
n (%) 
Age  
Median, years  
Range, years  
≥65 years 
 
64·0 
38–87 
108 (47·0) 
 
62·0 
36–90 
91 (39·2) 
Race 
White 
Asian 
Black or other 
 
175 (76·1) 
36 (15·7) 
19 (8·3) 
 
174 (75·0) 
34 (14·7) 
24 (10·3) 
Time from diagnosis of breast cancer 
to randomisation 
≤2 months 
>2 months to ≤1 year 
>1 year 
 
 
102 (44·3) 
58 (25·2) 
70 (30·4) 
 
 
99 (42·7) 
66 (28·4) 
67 (28·9) 
Receptor status 
ER+/PgR+ 
ER+/PgR- 
ER+/PgR unknown 
 
175 (76·1) 
44 (19·1) 
10 (4·3) 
 
179 (77·2) 
43 (18·5) 
7 (3·0) 
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ER-/PgR+ 
ER-/PgR- 
1 (0·4) 
0 
3 (1·3) 
0 
HER2 status 
Positive 
Negative 
 
0 
230 (100) 
 
1 (0·4) 
231 (99·6) 
WHO performance statusa 
0 
1 
2 
 
117 (50·9) 
106 (46·1) 
7 (3·0) 
 
115 (49·6) 
105 (45·3) 
12 (5·2) 
Disease stage 
Locally advanced 
Metastatic 
 
28 (12·2) 
202 (87·8) 
 
32 (13·8) 
200 (86·2) 
Visceral diseaseb 
Bone/musculoskeletal only 
Breast only 
Skin/soft tissue only 
Other/non-visceral 
135 (58·7) 
24 (10·4) 
3 (1·3) 
8 (3·5) 
60 (26·1) 
119 (51·3) 
24 (10·3) 
2 (0·9) 
6 (2·6) 
81 (34·9) 
Measurable disease 193 (83·9) 196 (84·5) 
Prior treatmentc 
Chemotherapy 
     LA/MBCd 
     Adjuvant  
 
 
36 (15·7) 
35 (15·2) 
 
 
43 (18·5) 
27 (11·6) 
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     Neo-adjuvant 
Radiotherapy 
Immunotherapy 
Hormonal therapy 
11 (4·8) 
53 (23·0) 
0 
2 (0·9) 
16 (6·9) 
50 (21·6) 
0 
1 (0·4) 
aWHO performance status: 0=normal activity; 1=restricted activity; 2=in bed ≤50% of 
the time 
bIncludes patients with disease site at baseline of adrenal, bladder, CNS, oesophagus, 
liver, lung, peritoneum, pleura, renal, small bowel, stomach, pancreas, thyroid, colon, 
rectal, ovary, biliary tract, ascites, pericardial effusion, spleen, or pleural effusion 
cPrior to enrolment; categories are not mutually exclusive 
dIncludes first-line, second-line, third-line, metastatic, and palliative chemotherapies 
(two patients were reported as deviations for having received second-line 
chemotherapy and one patient was reported in error to have received three prior lines 
of chemotherapy) 
CNS=central nervous system. ER=estrogen receptor. HER2=human epidermal growth 
factor receptor. ITT=intent-to-treat. LA/MBC=locally advanced/metastatic breast 
cancer. PgR=progesterone receptor. WHO=World Health Organization 
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Table 2: Clinical benefit (ITT population) 
Best objective response Fulvestrant 500 mg 
(n=230) 
n (%) 
Anastrozole 1 mg 
(n=232) 
n (%) 
Clinical benefit   
Total 180 (78·3) 172 (74·1) 
Complete response 7 (3·0) 8 (3·4) 
Partial response 86 (37·4) 82 (35·3) 
Stable disease ≥24 weeks 87 (37·8) 82 (35·3) 
No clinical benefit   
Total 50 (21·7) 60 (25·9) 
Stable disease ≥8 and <24 weeks 9 (3·9) 22 (9·5) 
Progression 30 (13·0) 33 (14·2) 
RECIST progression 27 (11·7) 28 (12·1) 
Death 3 (1·3) 5 (2·2) 
Not evaluablea 11 (4·8) 5 (2·2) 
aOwing to incomplete post-baseline assessments for all non-evaluable patients 
ITT=intent-to-treat. RECIST=Response Evaluation Criteria in Solid Tumours 
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Table 3: Adverse events with a frequency of >5% in any treatment group 
regardless of causality (safety analysis population) 
Characteristic  Fulvestrant 500 mg 
(n=228) 
n (%) 
Anastrozole 1 mg 
(n=232) 
n (%) 
Patients with any AE 166 (72·8) 173 (74·6) 
Arthralgia 38 (16·7) 24 (10·3) 
Hot flush 26 (11·4) 24 (10·3) 
Fatigue 26 (11·4) 16 (6·9) 
Nausea 24 (10·5) 24 (10·3) 
Back pain 21 (9·2) 14 (6·0) 
ALT increased 16 (7·0) 7 (3·0) 
Myalgia 16 (7·0) 8 (3·4) 
Hypertension 15 (6·6) 21 (9·1) 
Insomnia 15 (6·6) 13 (5·6) 
Diarrhoea 14 (6·1) 13 (5·6) 
Constipation 13 (5·7) 11 (4·7) 
Pain in extremity 13 (5·7) 10 (4·3) 
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AST increased 12 (5·3) 8 (3·4) 
Cough 12 (5·3) 8 (3·4) 
Anaemia 9 (3·9) 20 (8·6) 
Dyspnoea 9 (3·9) 13 (5·6) 
Oedema peripheral 9 (3·9) 13 (5·6) 
AEs were graded according to Common Terminology Criteria for Adverse Events 
version 4·0 
AE=adverse event. ALT=alanine aminotransferase. AST=aspartate aminotransferase  
  
 
